This page shows the latest Pexa-Vec news and features for those working in and with pharma, biotech and healthcare.
Pexa-Vec (pexastimogene devacirepvec) – one of the new class of oncolytic virus therapies (OVT) – didn’t add to the efficacy of therapy when it was added to treatment with ... PHOCUS was testing whether a dose of Pexa-Vec given ahead of Nexavar
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid tumours with trial results due between now and the end of
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Accession was a born from a passion and a vision. A passion to harness the power of market access to...